Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT04590664
Phase
PHASE1/PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase I/II trial studies the side effects and best dose of Visudyne (liposomal verteporfin) and to see how well it works in treating patients with high grade EGFR-mutated glioblastoma that has come back (recurrent). Visudyne is FDA approved in combination with light to treat eye diseases. In this study we use Visudyne by itself like chemotherapy to kill tumor cells which may be sensitive to verteporfin.

Key Dates

Start date
Jan 15, 2021
Status verified
Feb 2025
Primary completion
Aug 15, 2025
Completion
Aug 15, 2025

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (verteporfin)
    Patients receive verteporfin IV over 83 minutes weekly for 6 weeks in cycle 1, then weekly for 5 weeks in subsequent cycles. Cycles repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Incidence of adverse events (Phase I) [ Time Frame: From study enrollment until 100 days after the last day of study participation ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Emory University Hospital/Winship Cancer InstituteAtlantaGeorgia30322
Autumn Lunceford
[email protected]
404-686-1638
William L Read, MD

Find similar trials in Atlanta, GA

By condition
Brain cancer
By specialty
OncologyNeuro-oncology
By research site
Emory University Hospital/Winship Cancer Institute· Atlanta, GA

Related Studies